[{"id":"8cf55ab0-20f6-44cb-8bda-ecaebf4b0cba","acronym":"I-SPY 2","url":"https://clinicaltrials.gov/study/NCT01042379","created_at":"2021-01-17T17:27:23.313Z","updated_at":"2025-02-25T12:25:36.876Z","phase":"Phase 2","brief_title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","source_id_and_acronym":"NCT01042379 - I-SPY 2","lead_sponsor":"QuantumLeap Healthcare Collaborative","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • ER negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • paclitaxel • Nerlynx (neratinib) • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • doxorubicin hydrochloride • Talzenna (talazoparib) • Verzenio (abemaciclib) • Zejula (niraparib) • cyclophosphamide • irinotecan • Jemperli (dostarlimab-gxly) • Tukysa (tucatinib) • letrozole • veliparib (ABT-888) • Libtayo (cemiplimab-rwlc) • MK-2206 • Datroway (datopotamab deruxtecan-dlnk) • Ziihera (zanidatamab-hrii) • ganitumab (AMG 479) • amcenestrant (SAR439859) • anvatabart opadotin (JNJ-0683) • metformin • Jivadco (trastuzumab duocarmazine) • Turalio (pexidartinib) • ganetespib (ADX-1612) • vepdegestrant (ARV-471) • Cosela (trilaciclib) • Fablyn (lasofoxifene) • DAN-222 • fianlimab (REGN3767) • Oraxol (oral paclitaxel/encequidar) • ladiratuzumab vedotin (SGN-LIV1A) • nelitolimod (SD-101) • patritumab (U3-1287) • rilvegostomig (AZD2936) • trebananib (AMG 386) • Kevzara (sarilumab) • Voyager-V1"],"overall_status":"Recruiting","enrollment":" Enrollment 5000","initiation":"Initiation: 03/01/2010","start_date":" 03/01/2010","primary_txt":" Primary completion: 12/01/2030","primary_completion_date":" 12/01/2030","study_txt":" Completion: 12/01/2031","study_completion_date":" 12/01/2031","last_update_posted":"2024-10-22"},{"id":"b7bc4ba0-3f1a-46bf-b47b-5737fa659611","acronym":"","url":"https://clinicaltrials.gov/study/NCT04291105","created_at":"2021-01-18T20:49:30.604Z","updated_at":"2024-07-02T16:35:07.777Z","phase":"Phase 2","brief_title":"Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients","source_id_and_acronym":"NCT04291105","lead_sponsor":"Vyriad, Inc.","biomarkers":" PD-L1 • BRAF • MSI","pipe":" | ","alterations":" BRAF V600","tags":["PD-L1 • BRAF • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • Libtayo (cemiplimab-rwlc) • Voyager-V1"],"overall_status":"Recruiting","enrollment":" Enrollment 87","initiation":"Initiation: 04/24/2020","start_date":" 04/24/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2024-04-24"},{"id":"ffc8a32c-68db-4534-a945-fc26f36f0ec5","acronym":"","url":"https://clinicaltrials.gov/study/NCT03647163","created_at":"2021-01-18T17:54:10.954Z","updated_at":"2024-07-02T16:35:08.200Z","phase":"Phase 1/2","brief_title":"Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors","source_id_and_acronym":"NCT03647163","lead_sponsor":"Vyriad, Inc.","biomarkers":" PD-L1 • IFNB1","pipe":"","alterations":" ","tags":["PD-L1 • IFNB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • Voyager-V1"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 04/09/2019","start_date":" 04/09/2019","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-04-23"},{"id":"4d03b67b-68b2-483a-a512-97aaeedafd94","acronym":"","url":"https://clinicaltrials.gov/study/NCT03865212","created_at":"2021-01-18T19:03:32.995Z","updated_at":"2024-07-02T16:35:24.120Z","phase":"Phase 1","brief_title":"Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma","source_id_and_acronym":"NCT03865212","lead_sponsor":"Mayo Clinic","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VSV-IFNbetaTYRP1 • Voyager-V1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 06/12/2019","start_date":" 06/12/2019","primary_txt":" Primary completion: 01/20/2027","primary_completion_date":" 01/20/2027","study_txt":" Completion: 01/20/2027","study_completion_date":" 01/20/2027","last_update_posted":"2024-01-09"},{"id":"563fce28-b607-449e-9a82-ad3314d74409","acronym":"","url":"https://clinicaltrials.gov/study/NCT02923466","created_at":"2021-06-23T23:54:05.062Z","updated_at":"2024-07-02T16:36:11.374Z","phase":"Phase 1","brief_title":"Ph1 Administration of VSV-IFNβ-NIS Monotherapy and in Combination With Avelumab in Pts With Refractory Solid Tumors","source_id_and_acronym":"NCT02923466","lead_sponsor":"Vyriad, Inc.","biomarkers":" IFNB1","pipe":"","alterations":" ","tags":["IFNB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • Voyager-V1"],"overall_status":"Completed","enrollment":" Enrollment 76","initiation":"Initiation: 04/17/2017","start_date":" 04/17/2017","primary_txt":" Primary completion: 02/05/2022","primary_completion_date":" 02/05/2022","study_txt":" Completion: 04/22/2022","study_completion_date":" 04/22/2022","last_update_posted":"2022-04-27"}]